by Proxiva Peptides | Mar 5, 2026 | Research Guides
The Weight Loss Peptide Revolution Is Just Beginning The success of semaglutide and tirzepatide has proven that peptide-based therapies can produce weight loss previously achievable only through bariatric surgery. But as transformative as these compounds are, they...
by Proxiva Peptides | Mar 5, 2026 | Research Guides
A Landmark Year for Peptide Science 2026 has been an extraordinary year for peptide research, with breakthroughs spanning drug development, delivery technology, AI-driven design, and fundamental science. From the continued evolution of multi-agonist metabolic peptides...
by Proxiva Peptides | Mar 5, 2026 | Research Guides
The Peptide Revolution Goes Mainstream In 2024-2026, peptides went from niche biohacking compounds to mainstream cultural phenomenon. The transformation was driven by the explosive success of GLP-1 agonists like semaglutide (Ozempic/Wegovy) and tirzepatide...
by Proxiva Peptides | Mar 5, 2026 | Research Guides
What Are Peptides? Peptides are short chains of amino acids — the same building blocks that make up proteins — linked together by peptide bonds. While proteins typically contain 50 or more amino acids and fold into complex three-dimensional structures, peptides are...
by Proxiva Peptides | Mar 5, 2026 | Research Guides
The Evolving FDA Stance on Peptides The regulatory landscape for peptides in the United States has undergone dramatic shifts since 2023, creating uncertainty for researchers, compounding pharmacies, and the broader peptide industry. The FDA’s actions — from...
by Proxiva Peptides | Mar 5, 2026 | Research Guides
The Two Giants of GLP-1 Weight Loss Research Tirzepatide and semaglutide are the most effective anti-obesity peptides ever developed, each producing weight loss that was considered impossible with pharmacotherapy just a decade ago. But while both target the GLP-1...
